22:05:09 EDT Tue 04 Oct 2022
Enter Symbol
or Name

Login ID:
Tilray Inc
Symbol TLRY
Shares Issued 446,156,841
Close 2022-01-25 C$ 7.24
Recent Sedar Documents

Tilray offers medical pot whole flower in Australia

2022-01-25 09:27 ET - News Release

Ms. Denise Faltischek reports


Tilray Brands Inc. has expanded its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for health care providers.

Denise Faltischek, head of international and chief strategy officer, said: "Tilray is transforming the industry globally with our highly scalable footprint and portfolio of diverse cannabis products. As medical cannabis demand increases worldwide, we remain committed to providing health care professionals and patients with safe and reliable access to the highest-quality medical cannabis products." Ms. Faltischek continued, "After listening to patient feedback and leveraging learnings from our operations in Germany, we are excited to be introducing new products in Australia that meet consumer needs."

Tilray's product offering in Australia approved under the Therapeutic Goods Administration (TGA) special access and authorized prescriber scheme is centred around its whole flower options ranging from balanced 1:1 whole flower (THC 10/CBD 10), including mid-range (17) and high-THC (25) varieties of 15-gram bag GMP-certified (good manufacturing practice) medical cannabis whole flower.

George Polimenakos, general manager, Tilray Australia and New Zealand, said: "We are committed to providing reliable access to patients in need with pharmaceutical-grade medical cannabis products and are pleased to be expanding our medical cannabis offerings in Australia." Mr. Polimenakos continued, "On a related note, cannabis education is paramount to everything we do and are therefore excited to offer health care professionals with the tools they need to learn about cannabis through our new e-learning platform."

Tilray's new medical cannabis educational platform for health care professionals is built on the importance of understanding the benefits derived from medical cannabis use. To date, Tilray has successfully introduced multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of health care practitioners in 2021.

In addition to supplying hospitals and pharmacies, Tilray is a proud partner with several leading research institutions, including the Murdoch Children's Research Institute in Australia, studying the effectiveness of Tilray medical cannabis as a treatment for pediatric patients with intellectual disabilities suffering from severe behavioural problems; a clinical trial in partnership with the government of New South Wales and the University of Sydney Chris O'Brien Lifehouse to develop a novel treatment for chemotherapy-induced nausea; and a study led by the University of Sydney examining the effects of driving under the influence of cannabis.

Today, Tilray is one of the leading providers of GMP-certified medical cannabis to patients, physicians, pharmacies, hospitals, governments and researchers across the globe.

About Tilray Brands Inc.

Tilray Brands is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better -- one person at a time -- by inspiring and empowering people worldwide to live their very best lives by providing them with products that meet the needs of their minds, bodies and souls and invoke a sense of well-being. Tilray's mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and well-being through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray's unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and alcoholic beverages.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.